Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in Acute Decompensated Heart Failure (CANA-AHF)
NCT05364190Phase 3Completed
- Sponsor
- October 6 University
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of canagliflozin in heart failure (HF), sponsored by October 6 University. Started Jun 2022; status: completed.
02
Drugs
canagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05364190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364190.